home / stock / lexxw / lexxw news


LEXXW News and Press, Lexaria Bioscience Corp. Warrant From 07/28/23

Stock Information

Company Name: Lexaria Bioscience Corp. Warrant
Stock Symbol: LEXXW
Market: NASDAQ
Website: lexariabioscience.com

Menu

LEXXW LEXXW Quote LEXXW Short LEXXW News LEXXW Articles LEXXW Message Board
Get LEXXW Alerts

News, Short Squeeze, Breakout and More Instantly...

LEXXW - Lexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine Study

KELOWNA, BC / ACCESSWIRE / July 28, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has incorporated a new wholly-owned subsidiary under the name Lexaria Nutraceutical Corp. (" LEXX Nutra "). Th...

LEXXW - Lexaria Granted Strategically Important New US Patent for DehydraTECH-Nicotine Including Oral Pouch Products

(TheNewswire) More countries are banning e-cigarettes as novel oral products gain traction Kelowna, British Columbia – TheNewswire - July 19, 2023 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or “Le...

LEXXW - Lexaria Granted Strategically Important New US Patent For DehydraTECH-Nicotine Including Oral Pouch Products

More countries are banning e-cigarettes as novel oral products gain traction KELOWNA, BC / ACCESSWIRE / July 19, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has been granted a strategica...

LEXXW - Lexaria's Groundbreaking Research into DehydraTECH-CBD Published in International Journal of Molecular Science

DehydraTECH-CBD now featured in eight published, peer-reviewed papers KELOWNA, BC / ACCESSWIRE / June 22, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that its groundbreaking research utilizi...

LEXXW - InvestorNewsBreaks - Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands IP Portfolio with Four New Patents

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced its receipt of four newly granted patents. The company secured two new Canadian patents, its 18th in its patent family No. 1: Food and Beverage Compositions Infused with Lipophilic Active Age...

LEXXW - Lexaria Receives New Patents

Total of 6 new granted patents received by Lexaria so far in 2023 Lexaria now holds 34 granted patents world-wide KELOWNA, BC / ACCESSWIRE / June 20, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms ...

LEXXW - Lexaria's DehydraTECH-CBD Lowers Blood Glucose Levels in Diabetes Animal Study

Blood glucose levels reduced by 19.9% with DehydraTECH-CBD Improvements in kidney function also demonstrated KELOWNA, BC / ACCESSWIRE / June 16, 2023 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pl...

LEXXW - InvestorNewsBreaks - Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints Experienced Financial Professional as New CFO

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced the appointment of a new chief financial officer. Effective immediately, Mike Shankman will serve as outsourced CFO. An experienced accounting and finance professional, Shankman has held seni...

LEXXW - Lexaria Appoints New Chief Financial Officer

(TheNewswire) Kelowna, British Columbia – TheNewswire - June 12, 2023 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces the appointment of a new ...

LEXXW - InvestorNewsBreaks - Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Findings from DehydraTECH-CBD Hypertension Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced additional findings from last year’s human clinical study HYPER-H21-4. The findings demonstrate significant reductions in several pro-inflammatory biomarkers known to be linked to card...

Previous 10 Next 10